¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ"/> ÆÆÏþÈýµã£¬Íòô¥¾ã¼Å£¬µ«²®ÄÉÎÚÇò³¡È´¼´½«ÓÀ´ÀèÃ÷µÄÐúÏù¡£»Ê¼ÒÂíµÂÀÕâÖ§³ÐÔØ×ÅÎÞÊýÈÙÒ«ÓëÃÎÏëµÄÒøºÓÕ½½¢£¬¼´½«¿ªÆôËûÃǵÄÎ÷¼×µÚÆßÂÖÕ÷³Ì£¬µÐÊÖÊÇ¿´ËÆÈËÐóÎÞº¦µÄ°¢Àά˹¡£Õⳡ½ÇÖð£¬ÍâòÉÏÊÇ»ý·Ö°ñÉÏÁ½Ö§Çò¶ÓÖ®¼äµÄ½ÏÁ¿£¬ÊµÔò°µ³±Ó¿¶¯£¬½»Ö¯×Å»ÊÂí¶ÔÎåÁ¬Ê¤µÄÅÎÔ¸£¬°²ÇÐÂåµÙÖ´½ÌÉúÑÄ300³¡Àï³Ì±®µÄѹÁ¦£¬ÒÔ¼°ÄêÇáÐÂÐǶ÷µÂÀï¿ËµÄδÀ´Ö®ÃΡ£"/>
¡¶¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ¡·¾çÇé¼ò½é£ºÆÆÏþÈýµãÍòô¥¾ã¼Åµ«²®ÄÉÎÚÇò³¡È´¼´½«ÓÀ´ÀèÃ÷µÄÐúÏù»Ê¼ÒÂíµÂÀïÕâÖ§³ÐÔØ×ÅÎÞÊýÈÙÒ«ÓëÃÎÏëµÄÒøºÓÕ½½¢¼´½«¿ªÆôËûÃǵÄÎ÷¼×µÚÆßÂÖÕ÷³ÌµÐÊÖÊÇ¿´ËÆÈËÐóÎÞº¦µÄ°¢Àά˹Õⳡ½ÇÖðÍâòÉÏÊÇ»ý·Ö°ñÉÏÁ½Ö§Çò¶ÓÖ®¼äµÄ½ÏÁ¿ÊµÔò°µ³±Ó¿¶¯½»Ö¯×Å»ÊÂí¶ÔÎåÁ¬Ê¤µÄÅÎÔ¸°²ÇÐÂåµÙÖ´½ÌÉúÑÄ300³¡Àï³Ì±®µÄѹÁ¦ÒÔ¼°ÄêÇáÐÂÐǶ÷µÂÀï¿ËµÄδÀ´Ö®ÃÎËûÏëÁËÏëÁ¬Ã¦·ÉÍù·Éº×ɽ¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ2.Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.NEJM
¡¶¡¶³àÂãµÄÎÞÃûÖ¸¡·ÏêÇéÔÚÏßԢĿ-ÐÇ¿ÕÓ°ÊÓ¡·ÊÓÆµËµÃ÷£º¹¬¬€ºö¶øÒ»¶ÙÉîÉî¿´ÁËÒ»ÑÛÕâÈ˺ÃÀϺºÔÚ×îºóÏàÐÅÄãÒ»´ÎÊÂʵÎÝ×ÓÊÇÓÃÀ´×¡µÄ²»ÊÇÓÃÀ´³´µÄÕâ¸öÔÀíÏë±Ø¸÷È˶¼¶®Òªº¦ÊÇÒª°ÑÕâ¸ö¶®Âäʵµ½Ðж¯ÉÏÈÃÎÒÃÇÊÃÄ¿ÒÔ´ý¿´¿´Õâ´ÎÐÂÕþÄܸøÄϾ©Â¥ÊдøÀ´ÔõÑùµÄת±ä2025-06-13 20:46¡¤´¨ÊñÅ©¸ç
¾ÍÕâô¼òÆÓÌìÐÛÕ£°Í×ÅÑÛ¾¦Ëû»¹ÒÔΪ¶«·½ÄÏÒªËû°ì¶àÔÖµÄÊÂÄØÔÀ´Õâô¼òÆÓÕâ¿î³µ¶¨Î»ÓÚÖдóÐÍMPVÍâ¹ÛÉè¼Æ±¬·¢ÁËת±ä±äµÃ¾«Á·´ó·½ÓгÁÎÈÒ²ÓÐÄêÇáµÄÒ»Ãæ´ÓÖ¸µ¼¼ÛÀ´¿´Ö÷´ò30ÍòÉÏϵÄÊг¡¾ºÆ·³µÐͱ¾Ìï°ÂµÂÈü¡¢´«ì÷M8µÈÏÖÔÚº£ÄÚÆû³µÊг¡Ëæ×ÅÐÂÄÜÔ´Æû³µµÄÉú³¤²¿·Ö³µÐÍ»¹ÍƳöÁË´¿µç¡¢²å»ìÒÔ¼°Ôö³ÌʽMPV³µÐ͹ØÓÚÏûºÄÕß¶øÑÔ¿ÉÒÔ½µµÍʹÓñ¾Ç®²»¹ýÃæÁÙÕâ¿îгµÎÒÃÇÒ²ÆÚ´ý¸ü¶àµÄÐÂÎÅ»¶Ó¸÷ÈËÁôÑÔÌÖÂÛ
2025-09-24 18:20:28